

## Safety and PCR monitoring in 161 semi-immune Kenyan adults following controlled human malaria infection

Melissa C. Kapulu, ... , Edward Otieno, Peter F. Billingsley

JCI Insight. 2021. <https://doi.org/10.1172/jci.insight.146443>.

Clinical Medicine

In-Press Preview

Clinical trials

Infectious disease

**BACKGROUND.** Naturally acquired immunity to malaria is incompletely understood. We used controlled human malaria infection (CHMI) to study the impact of past exposure to malaria in Kenyan adults in relation to infection with a non-Kenyan parasite strain.

**METHODS.** We administered  $3.2 \times 10^3$  aseptic, purified, cryopreserved *Plasmodium falciparum* (Pf) sporozoites (SPZ) [Sanaria® PfSPZ Challenge, NF54 West African strain] by direct venous inoculation and undertook clinical monitoring and serial quantitative PCR (qPCR) of the *18S* ribosomal RNA gene. The study endpoint was met when either: parasitaemia reached  $\geq 500$  parasites/ $\mu$ l blood; clinically significant symptoms were seen; or at 21 days after inoculation. All volunteers received antimalarial drug treatment on meeting the endpoint.

**RESULTS.** One hundred and sixty-one (161) volunteers underwent CHMI between Aug 4, 2016, and Feb 14, 2018. CHMI was well tolerated with no severe or serious adverse events. Nineteen volunteers (11.8%) were excluded from the analysis based on detection of antimalarial drugs above the minimal inhibitory concentration or parasites genotyped as non-NF54. Of the 142 volunteers who were eligible for analysis: 26 (18.3%) had febrile symptoms and were treated; 30 (21.1%) reached  $\geq 500$  parasites/ $\mu$ l and were treated; 53 (37.3%) had parasitaemia without [...]

Find the latest version:

<https://jci.me/146443/pdf>



Title: Safety and PCR monitoring in 161 Semi-Immune Kenyan Adults following Controlled Human Malaria Infection

Authors:

Melissa C Kapulu,<sup>1,2\*</sup> Patricia Njuguna,<sup>1#</sup> Mainga Hamaluba,<sup>1,2</sup> Domtila Kimani,<sup>1</sup> Joyce M. Ngoi,<sup>1</sup> Janet Musembi,<sup>1</sup> Omar Ngoto,<sup>1</sup> Edward Otieno,<sup>1</sup> Peter F Billingsley,<sup>3</sup> and CHMI-SIKA Study Team

Affiliations:

<sup>1</sup>Centre for Geographic Medicine Research (Coast), Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya

<sup>2</sup>Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University Oxford, Oxford, UK

<sup>3</sup>Sanaria Inc., Rockville, Maryland, USA

<sup>#</sup>Current address is: World Health Organisation, Geneva, Switzerland

**Conflict of interest:** Y. Abebe, P.F. Billingsley, S.L. Hoffman, E.R. James, T.L. Richie, and B.K.L. Sim are salaried, full-time employees of Sanaria Inc., the manufacturer of Sanaria PfSPZ Challenge.

\*Address correspondence to: Melissa C Kapulu, Centre for Geographic Medicine Research (Coast), Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya; Telephone number +254709983463; Email address: [mkapulu@kemri-wellcome.org](mailto:mkapulu@kemri-wellcome.org)

Role of funding source: This work was funded by the Wellcome Trust. The funder had no role in the design, analysis, write-up or decision to submit for publication.

**Abstract:**

**Background:** Naturally acquired immunity to malaria is incompletely understood. We used controlled human malaria infection (CHMI) to study the impact of past exposure to malaria in Kenyan adults in relation to infection with a non-Kenyan parasite strain.

**Methods:** We administered  $3.2 \times 10^3$  aseptic, purified, cryopreserved *Plasmodium falciparum* (Pf) sporozoites (SPZ) [Sanaria® PfSPZ Challenge, NF54 West African strain] by direct venous inoculation and undertook clinical monitoring and serial quantitative PCR (qPCR) of the *18S* ribosomal RNA gene. The study endpoint was met when either: parasitaemia reached  $\geq 500$  parasites/ $\mu$ l blood; clinically significant symptoms were seen; or at 21 days after inoculation. All volunteers received antimalarial drug treatment on meeting the endpoint.

**Results:** One hundred and sixty-one (161) volunteers underwent CHMI between Aug 4, 2016, and Feb 14, 2018. CHMI was well tolerated with no severe or serious adverse events. Nineteen volunteers (11.8%) were excluded from the analysis based on detection of antimalarial drugs above the minimal inhibitory concentration or parasites genotyped as non-NF54. Of the 142 volunteers who were eligible for analysis: 26 (18.3%) had febrile symptoms and were treated; 30 (21.1%) reached  $\geq 500$  parasites/ $\mu$ l and were treated; 53 (37.3%) had parasitaemia without meeting thresholds for treatment and; 33 (23.2%) remained qPCR negative.

**Conclusion:** We find that past exposure to malaria, as evidenced by location of residence, in some Kenyan adults can completely suppress in vivo growth of a parasite strain originating from outside Kenya.

**Trial registration:** The study was registered on ClinicalTrials.gov (NCT02739763).

**Funding:** Wellcome Trust

## **Introduction**

Humans become immune to *Plasmodium falciparum* malaria following repeated exposure (1). Immuno-epidemiological studies show associations between immune responses and protection against malaria in the field (2), but their interpretation is complicated by heterogeneity of exposure (3). Furthermore, malaria is genetically diverse and vaccines that protect against heterologous parasites are required for sustained public health impact. Exposure in the field is usually with parasites of unknown genotype, further complicating inferences on protective immunity. An experimental design with controlled exposure to parasites, such as the controlled human malaria infection model, is needed for greater confidence in inferring causality and to directly test for heterologous immunity.

Human infection studies in which investigators intentionally infect healthy volunteers have been used to understand pathogenesis, immunity, and genetic resistance to infection, and to measure the efficacy of drugs and vaccines (4). The majority of controlled human malaria infection (CHMI) studies done to date have used *P. falciparum* (Pf)-infected mosquitoes to assess vaccine-induced efficacy in non-malaria endemic populations. The availability of aseptic, purified cryopreserved Pf sporozoites (SPZ) (PfSPZ Challenge), administered by needle and syringe has facilitated CHMI studies among non-endemic and endemic populations (5–7). An intravenous dose of  $3.2 \times 10^3$  PfSPZ leads to an established infection with exponential in vivo parasite growth in 100% of volunteers from malaria non-endemic areas (8, 9).

PfSPZ Challenge has now been used in several malaria endemic populations. A total of 150 volunteers in four malaria endemic countries (Gabon, Gambia, Kenya, and Tanzania), have been enrolled in published CHMI studies using PfSPZ Challenge to either assess vaccine efficacy or infectivity (6, 7, 10–12). These studies have been used to evaluate vaccine efficacy

(12); naturally-acquired immunity (6, 7, 10); and innate resistance to infection (11). A further 300 volunteers have been or will be enrolled in vaccine efficacy CHMI trials in West and East Africa over the next 2-3 years (13). Most of the volunteers in these CHMI studies were from urban areas (i.e. with limited prior malaria exposure). Nevertheless, this limited prior exposure led to CHMI outcomes in these individuals that were different from those seen in non-endemic regions (6, 7, 10, 11). Ten of 43 volunteers did not develop positive blood smears for malaria parasites in studies in Tanzania (6) and Gabon (11), whereas 100% of volunteers in non-endemic areas develop positive blood smears. In a vaccine efficacy study conducted in Tanzania (12), infectivity detectable by blood smear microscopy in the control group was observed in 16 of 18 volunteers. In Kenya, Nairobi, one of 28 volunteers were negative by blood smear microscopy, and showed minimal parasite growth by serial quantitative polymerase chain reaction (qPCR) (7). In The Gambia, 17 of 19 volunteers developed infection detectable by microscopy, one was negative by microscopy but positive by qPCR, and another one was negative by qPCR (10).

For endpoint assessment in CHMI studies, the conventional method for monitoring parasitaemia has been thick blood smear microscopy which does not detect low-density parasitaemia (14). Molecular markers such as qPCR are substantially more sensitive (15), and therefore provided more information on parasite growth in the CHMI studies referenced above in Kenya and in Gambia. This molecular marker-based approach has recently been qualified by the USA Food and Drug Administration (FDA) as a replacement for thick blood smears in non-endemic CHMI studies (16).

To systematically explore qPCR outcomes following CHMI in semi-immune adults, we conducted the largest CHMI study to date, recruiting volunteers with previous exposure to

malaria from specific rural areas in Kenya. As adults in malaria-endemic regions of Kenya are frequently found to be asymptomatic despite significant blood parasitaemia (17), we adopted a relatively high threshold (500 parasites per  $\mu\text{L}$ ) for the study endpoint. This threshold is higher than that used for CHMI in non-endemic areas (where thick blood smear microscopy has been the criteria for treatment, equivalent to  $\sim 5\text{-}50$  parasites per  $\mu\text{L}$ ) (15). However, we expected parasites would be well tolerated among Kenyan adults, since the threshold is five times below the parasitaemia associated with symptomatic malaria in Kenyan children (i.e. 2,500 parasites per  $\mu\text{L}$ ) (17). We included criteria for treatment at lower parasite densities in the presence of significant clinical symptoms.

The aim of this study was to investigate how the *in vivo* parasite growth in CHMI would be modified by pre-existing immunity, where qPCR was used to quantify parasite growth and PfNF54 parasites were used for challenge. NF54 is a laboratory-adapted parasite line that is of West African origin and is genetically distinct from East African parasites (18). Moser et al (2020) have recently shown that East African parasites (including parasite clinical isolates from Kenya) are genetically distant from NF54 parasites (18). Based on phylogenetic analysis, NF54 has been shown to cluster with West African parasites. The genetic distance between NF54 and East African parasites is similar to the distance with South American parasites, and therefore cross-protection against NF54 can be attributed to exposure to genetically distant parasites.

## **Results**

### ***Study design and study population***

504 volunteers were recruited from Ahero, Kilifi North, and Kilifi South locations in Kenya and assessed for eligibility. Of these, 161 healthy volunteers were enrolled into three successive cohorts beginning in August 2016, February 2017, and February 2018 (N=37, 64 and 60,

respectively) representative of volunteers from Ahero (N=15), Kilifi North (N=34), and Kilifi South (N=112). All 161 volunteers were inoculated with  $3.2 \times 10^3$  PfSPZ of PfSPZ Challenge NF54 by DVI and monitored for outcomes by clinical assessment and qPCR. All volunteers completed CHMI and were successfully treated and discharged from inpatient care (**Figure 1**). One hundred and sixty-one volunteers completed CHMI and these were considered to have completed CHMI if they if they had received endpoint treatment. Out of these, one hundred and fifty-eight volunteers completed follow-up at day 35 post-CHMI (day 90 for the 2016 cohort). Two volunteers moved away from the study area, and one was not available for follow-up visit(s) after CHMI was completed. Data from these two volunteers were included for analysis of CHMI outcomes. Seven volunteers were found to have non-PfNF54 strain parasites (**Supplementary File 1**) and excluded from further analysis, and a further twelve volunteers were excluded on the basis of anti-malarial drug concentrations (detected at C-1 and C+8 timepoints, see below) (**Supplementary File 2**). Thus, the safety analysis is reported for all 161 volunteers who underwent CHMI and qPCR outcomes are described for 142 volunteers (**Figure 1**). The mean age at enrolment was 29.5 years old (SD 7.1) and most volunteers were male (70.2%) (**Table 1**). The baseline characteristics of the 161 enrolled volunteers are shown in **Table 1**.

### *Adverse events*

There were no serious adverse events reported. Adverse event reporting was divided into three separate time periods: (a) the first six days from day of administration of PfSPZ (1-7), where there were few grade 1 local adverse events relating to the injection site and some isolated unsolicited events; (b) Day 8 after administration of PfSPZ up to day of treatment (8-DoT) when systemic febrile events (e.g. headache followed by fever, myalgia, and sweating) became more common; and (c) day of treatment to exit from in-patient stay (DoT-Exit) when systemic febrile adverse events were most common (**Table 2**). Unsolicited adverse events reflected

symptoms of febrile malaria with a few additional events at low frequency. Solicited and unsolicited adverse events were all found to be mild (i.e. grade 1). The most common adverse event reported was headache followed by fever, myalgia, and sweating. The most commonly used concomitant medications were anti-pyretics (**Supplementary Table 2**).

The most common abnormalities on safety blood tests during CHMI were Grade 1 and 2 elevated alanine aminotransferase (ALT) and creatinine values, all of which resolved to within the normal range during the follow-up period (**Supplementary Table 3**). The cut-offs for ALT grade 1 were >80 to <200 IU/L and >55 to <138 IU/L whilst grade 2 were 200 to <400 IU/L and 138 to <275 IU/L respectively for males and females. The cut-offs for creatinine grade 1 were >111 to 144  $\mu\text{mol/L}$  and >92 to <119  $\mu\text{mol/L}$  whilst grade 2 were >144 to 199  $\mu\text{mol/L}$  and >119 to <166  $\mu\text{mol/L}$  respectively for males and females. ALT increases were more common in males compared with females (**Supplementary Figure 1**). Markedly reduced platelet counts (Grade 4) were observed in two volunteers, as has previously been described in malaria (19). There were no signs of any bleeding tendency, consistent with previous reports of severe thrombocytopenia in malaria (19).

#### *Assessment of presence of anti-malarial drugs*

Anti-malarial drugs were detected in some volunteers (**Table 3** and **Supplementary Figure 3**). Two volunteers had detectable concentrations of chloroquine (i.e. 3.6 ng/ml and 5 ng/ml) prior to CHMI, both at concentrations well below the reported minimum inhibitory concentration (MIC) of 67 ng/ml (20) (i.e. at 5 ng/ml plasma and 3.6 ng/ml plasma); one of these met criteria for treatment before Day 22, the other did not. Twelve volunteers had lumefantrine concentrations above the reported MIC of 280 ng/ml plasma (21), none of whom met criteria for treatment. A further 64 volunteers had concentrations below the MIC, of whom

43 met criteria for treatment before day 22, and 21 did not. Thus, among volunteers with detectable lumefantrine concentrations (albeit below the MIC), criteria for treatment were met slightly less often than among volunteers in whom lumefantrine was undetectable, 33.4% (25/73) vs 43.5% (33/76) ( $p=0.25$ , **Table 3**).

One volunteer had high concentrations of both pyrimethamine and sulfadoxine and did not meet criteria for treatment. Two further volunteers had detectable concentrations of sulfadoxine without pyrimethamine and both met criteria for treatment before Day 22. There was no detectable artemether or dihydroartemisinin in any sample. The prevalence of detectable lumefantrine concentrations was higher in Kilifi South (62.5%, 70/112) compared to Kilifi North (20.6%, 7/34). Lumefantrine concentrations measured at the two independent laboratories were closely correlated ( $r=0.93$ ,  $p<0.0001$ ).

#### ***Analysis of qPCR outcome following CHMI***

For further analysis of qPCR outcomes by location we therefore excluded volunteers with lumefantrine concentrations above the MIC and we excluded the volunteer with high pyrimethamine and sulfadoxine concentrations. Concentrations of chloroquine or of lumefantrine below the MIC were not strongly associated with outcome and therefore we retained data from volunteers with these drug levels and those with undetectable drug levels. Thus, we included data from 142 volunteers for further analysis (**Table 3**). One volunteer requested early treatment at C+21 therefore was missing qPCR data from C+22. The volunteer was qPCR negative up to day 21, and it was therefore assumed they would be negative at day 22 and their data were included in the final analysis.

We combined our data from Kilifi and Ahero with data from a previous pilot CHMI study conducted in Nairobi (an urban area with no malaria transmission) (7). The qPCR results over time in relation to location, outcome, and febrile status are shown in **Figure 2**. Heterogeneous patterns of parasite growth were observed over time with: (a) some volunteers showing rapid and consistent growth; (b) others showing early parasite growth that subsequently appeared to be suppressed; (c) late growth that was inconsistent and did not reach the threshold criteria for treatment; or (d) negative qPCR results throughout the period of monitoring. Individual qPCR results for each volunteer are shown as supplementary figures for the respective locations – Nairobi, Ahero, Kilifi North, and Kilifi South, (**Supplementary Figure 3**). In addition, individual qPCR results are shown for each respective successive cohort 2016, 2017 and 2018 (**Supplementary Figure 4**).

Of the 142 volunteers resident in Kilifi or Ahero (i.e. excluding Nairobi residents): 26 (18.3%) had febrile symptoms and were treated; 30 (21.1%) reached  $\geq 500$  parasites/ $\mu\text{l}$  and were treated; 53 (37.3%) had parasitaemia without meeting thresholds for treatment and; 33 (23.2%) remained qPCR negative, 10 of these with no detectable antimalarial drug levels (**Supplementary Table 4**). Of the 28 volunteers previously included in CHMI in Nairobi, all experienced parasite growth with 27 (96.4%) meeting the criteria for malaria diagnosis and one volunteer (3.6%) had parasitaemia without meeting thresholds for treatment (7). **Table 4** shows the distribution of these qPCR outcomes by location. Criteria for treatment were more frequently met among volunteers from Nairobi and Kilifi North, and less frequently met for volunteers from Ahero or Kilifi South (**Table 4**).

In contrast, in the high transmission locations of Kilifi South and Ahero it was more common to observe volunteers that experienced limited parasite growth or with negative qPCR results.

The presence of fever was more common in Kilifi North than in Kilifi South or in Ahero. Fever was less frequent in the Nairobi study where treatment was given based on microscopy (microscopy is positive at 50 parasites/ $\mu$ l by qPCR assay (14) but volunteers were treated at 500 parasites/ $\mu$ l blood in the present study). Similar results were seen after excluding all volunteers with detectable lumefantrine concentrations (**Supplementary Table 4**).

### ***PCR parasite detection comparisons***

A subset of samples from the 2018 enrolment cohort, a total of 120 samples corresponding to 20 volunteers from time points C+8 to C+10.5 (8 volunteers who were qPCR negative throughout in Kilifi and 12 other volunteers with positive readings), were shared with two external laboratories at Mahidol University (MU), Thailand and at University of Washington (UW), USA for their analytically sensitive qPCR and reverse transcription PCR (RT-PCR) assays, respectively(15, 16, 22). There was close agreement of results from the Kilifi laboratory assay with those of MU ( $r=0.65$ ,  $p<0.0001$ ) and UW ( $r=0.64$ ,  $p<0.0001$ ), and between MU and UW assays ( $r=0.79$ ,  $p<0.0001$ ) (**Supplementary Figure 5**). Of the eight volunteers considered qPCR negative in the Kilifi assay, five had parasitaemia detected at low levels in the MU assay and six had low-level parasitaemia in the UW assay (**Supplementary Figure 6**). Two of the eight volunteers were negative for all the three assays whilst one volunteer was positive for the UW assay but negative for the other two assays.

Finally, we re-analysed the ALT elevations observed after CHMI according to qPCR outcomes and found that ALT elevations did not vary according to qPCR status. Volunteers who were qPCR negative for malaria parasites following CHMI had a median ALT of 46 (IQR 27-120) at Day 10, compared with a median ALT of 43 (IQR 26-80) among those who were qPCR positive ( $Z=0.79$ ,  $p=0.43$ ) (**Supplementary Figure 7**).

## Discussion

We found CHMI to be safe and well tolerated in the 161 volunteers enrolled in this study who were recruited from malaria-endemic regions of Kenya. Using qPCR, we show that outcomes following CHMI vary depending on previous history of malaria exposure. In malaria non-endemic locations, inoculation with the same dose of  $3.2 \times 10^3$  of PfSPZ Challenge by DVI that was used in our study leads to infection and in vivo parasite growth in 100% of volunteers (8, 9). In our study with Kenyan volunteers, we observed in vivo parasite growth leading to parasite densities meeting treatment criteria in only 39.5% of our volunteers (i.e. 18.3% with symptoms plus 21.1% without). In 37.3% of the volunteers we observed limited in vivo growth that was partially suppressed such that treatment criteria were not met. In another 23.3% of volunteers we observed complete suppression of parasite growth such that parasites were not detected by our qPCR assay. The challenge strain is genetically distant to East African parasites (18), implying that the complete suppression of parasite growth was the result of heterologous immunity.

We saw elevated levels of ALT following infection which reverted to baseline following clearance of infection. Other CHMI studies in malaria naïve volunteers have reported elevated levels of liver enzymes, seen after mosquito bite and blood-stage challenge and in both *P. falciparum* and *P. vivax* (23–26). Furthermore, Dondorp et al (2021) have observed increased liver enzymes following *P. falciparum* natural infection (27). Rises in liver enzymes appear more pronounced in naïve populations. In our study, these increases were more pronounced in male volunteers (**Supplementary Figure 1**) but were not associated with any clinical indicators of serious illness.

This study provides the largest dataset to date on CHMI outcomes in an adult population from a malaria-endemic area. The CHMI outcomes in participants from different locations clearly followed the underlying intensity of malaria exposure (i.e. with Nairobi appearing similar to

non-endemic countries, and then Kilifi North, Kilifi South, and Ahero associated with increasing control of parasite growth). It is likely that prior malaria exposure rather than human genetic differences explains the observed variations in CHMI outcomes. In relation to more recently published CHMI studies in endemic populations (6, 7, 10, 11), the findings here, based on qPCR as the main readout for endpoint outcome, demonstrates that using more sensitive molecular methods for endpoint readout as opposed to thick blood smear which has been traditionally used in other CHMI studies, infection with genetically distinct parasite has varying outcome depending on the current and/or past exposure to malaria. Previous CHMI studies have enrolled volunteers with historic past exposure and little to no current exposure (6, 7, 10), and here we show outcomes following CHMI that mirror the exposure patterns as evidenced by area of residence. Of note is the number of volunteers, who following infection do not have febrile malaria which is also appears to be as a result of current and/or past exposure.

In this study, anti-malarial drugs were detectable in a significant proportion of volunteers, particularly lumefantrine, which has a relatively long half-life (28). Thus, we excluded volunteers with baseline concentrations of lumefantrine above the reported minimum inhibitory concentration (MIC) for *P. falciparum* (21). We analysed lumefantrine concentrations below the MIC and found no association with CHMI outcome in these volunteers, who were therefore retained in the analysis. Furthermore, there was a similar pattern of results seen when we re-analyzed data after excluding all volunteers with detectable lumefantrine concentrations (**Supplementary Table 4**). Artemether-lumefantrine is widely available in Kenya, and is the likely source of lumefantrine in our volunteers (29). Artemisinin were not detected in any volunteers, and these drugs have a very short half-life (30). The observed concentrations of lumefantrine were low or undetectable. Taking this together with the absent artemisinin plasma concentrations, we conclude that any putative doses of

artemether-lumefantrine were likely taken several weeks prior to CHMI. Although we solicited for history of anti-malarial use during the screening visit and excluded volunteers who reported recent treatment, volunteers may have previously taken medication with little or no explanation from medical staff. We therefore believe our findings are due to inadvertent or forgotten previous use of anti-malarial drugs rather than recent surreptitious anti-malarial use to influence outcomes of CHMI.

In some volunteers Kilifi qPCR results were negative throughout. The Kilifi assay has an analytical sensitivity of 20 estimated parasites/ml. Using a 0.5 or 1 ml sample, the UW qRT-PCR and the MU qPCR assays are both more sensitive than the Kilifi qPCR to parasite densities below 20 parasites/ml (15, 22). Using these more sensitive assays, 6 of 8 volunteers who were considered qPCR negative in Kilifi were found to have low level parasitemia by UW or MU assays. If we had assessed all 33 Kilifi qPCR volunteers with UW and MU assays, we might expect the negative qPCR rate to be reduced by a similar proportion from 23% to 6%. Repeated assays of increased blood sample volumes would likely further increase the sensitivity for detecting low density parasitaemia (15, 22). However, since there were two out of eight volunteers for whom all the samples analysed were negative with all the three qPCR assays, we cannot exclude the possibility of sterile pre-erythrocytic immunity in some volunteers. Furthermore, that parasites were undetectable in some volunteers immediately after emergence from the liver (i.e. 8.5-10.5 days post-CHMI) and then subsequently detectable suggests a low liver-to-blood inoculum (31), which would indicate a partial role for pre-erythrocytic-stage immune responses, albeit not necessarily sterile protection. Nevertheless, the suppression of parasite growth by host immunity is profound. Further studies are warranted and will include an analysis of parameters describing the PCR data (e.g. growth rates, time to reaching treatment

thresholds, mean densities) to identify those parameters most closely reflecting host immunity, and an analysis of potential biomarkers of host immunity.

In conclusion, we have shown CHMI studies to be safe in a malaria endemic location. Past exposure to malaria in an adult population leads to a range of outcomes in CHMI studies in malaria-endemic regions. *P. falciparum* shows marked antigenic diversity, which results in parasites evading host immunity (32). Our data suggest that sufficiently cross-reactive blood-stage immunity can be acquired on exposure to East African parasites to clear qPCR-detectable parasitaemia from a phylogenetically distant West African parasite (i.e. NF54).

## **Methods**

### **Study design and volunteer population**

The study was open, unblinded, and non-randomised. The protocol has been published previously (13). All volunteers received an intravenous injection (direct venous inoculation (DVI)) of  $3.2 \times 10^3$  PfSPZ of the West African NF54 strain (PfSPZ Challenge, i.e. aseptic, purified, cryopreserved PfSPZ). Volunteers were recruited from differing malaria endemic regions in Kenya: Ahero in Western Kenya (moderate to high transmission at community age-adjusted parasite rates (PfPR) of 40%); Kilifi South (moderate transmission, currently at a PfPR of 20% but historically a PfPR of 40%); and Kilifi North on the Kenyan Coast (low to no malaria transmission at present, but historically a PfPR of 25%) (33).

We included data from a previous study based in Nairobi where there is no malaria transmission (7), although volunteers may have been exposed during previous residence or childhood elsewhere in Kenya. The Nairobi CHMI study was conducted in a total of 28 volunteers with PfSPZ administered via the intramuscular route with doses of either 125,000 (N=20), 75,000 (N=4), or 25,000 (N=4) PfSPZ. In the Kilifi study real-time qPCR results were used for malaria

diagnosis, whereas criteria for malaria diagnosis in Nairobi were based on thick-blood film microscopy with retrospective analysis of qPCR results. A positive thick film corresponds to a qPCR quantification of ~50 parasites per  $\mu\text{L}$  (14).

### **Study enrolment and administration of PfSPZ Challenge**

For the current study in Kilifi, following recruitment and informed consent procedures, volunteers went through a screening process to determine their health status and past exposure to malaria. Furthermore, anti-schizont antibodies, as previously described (7), were measured at screening to ensure that the enrolled volunteers would include a range of anti-schizont antibody titres. This was done to ensure equal enrollment from each of the three tertiles of anti-schizont antibody titres identified at screening. A dose of  $3.2 \times 10^3$  PfSPZ was administered by direct venous inoculation in 0.5 mL through a 25-gauge needle over several seconds, after which volunteers were monitored for blood parasitaemia by qPCR to determine parasite growth. Volunteers were enrolled in three successive cohorts in 2016, 2017 and 2018.

### **Safety monitoring**

All volunteers were monitored for any adverse events (AEs), solicited and unsolicited, for the duration of CHMI. Signs and/or symptoms of malaria were assessed and recorded. Abnormal laboratory findings were graded for severity based on population sex-specific adapted reference ranges (**Supplementary Table 1**). These were categorised either as 'low' or 'high' where 'low' referred to values below to the lower normal limit range and 'high' to values above the upper normal limit range. In keeping with the study data tabulation model implementation guide for human clinical trials, the day of injection/inoculation was defined as day 1 (C1) and not day 0 (C0).

## **Quantitative PCR for parasite detection**

In the Kilifi study real-time qPCR results were used for endpoint criteria. Endpoint criteria were considered met and anti-malarial treatment given when: (a) parasitaemia reached 500 parasites/ $\mu$ l; (b) clinically significant signs and/or symptoms were observed, with any evidence of malaria parasites by blood film positivity; or (c) at day 22 (21 days post-infection). For criteria (b) thick and thin blood films were prepared when requested by the assessing clinicians and made from whole blood by experienced microscopists who examined 100 high power fields. In Nairobi endpoint criteria were met when thick-blood film microscopy was positive with retrospective analysis of qPCR results. A positive thick film corresponds to a qPCR quantification of  $\sim$ 50 parasites per  $\mu$ L (14).

For parasite detection, a sensitive high-volume qPCR assay, detecting the *18S* ribosomal RNA *P. falciparum* gene, was used in real time where 500  $\mu$ l of whole venous blood was collected twice every day from days 8 to 15 post infection and then once every day from days 16 to 22 post-infection (13). 500  $\mu$ l venous blood samples were used to extract DNA using an automated DNA extraction and purification method (QIASymphony platform, Qiagen, Germany) according to the manufacturer's instructions. DNA was eluted in 100  $\mu$ l of DNase free water/elution buffer from which 13.5  $\mu$ l was used to amplify the 18S ribosomal RNA gene by qPCR in triplicates in a hydrolysis probe assay using primers and probes previously described (34). The PCR cycling conditions were carried as described (34) using Applied Biosystems 7500 real-time PCR system. Non-template control was used as a negative control (in triplicate wells) with parasite quantification against known cultured parasite standards comprising of six serial dilutions of extracted DNA also run in triplicate. The theoretical sensitivity of this assay is 5 parasites/ml (i.e.  $[1000 \mu\text{l} / (13.5 \mu\text{l} \times 3/100 \mu\text{l})] \times 500 \mu\text{l}$ ) but based on serial dilutions and comparison with negative controls, we consider the actual sensitivity to be 20 parasites/ml.

The final result was the geometric mean of the three replicates (34). Cultured parasite standards were produced in three different batches across the three successive enrolled cohorts. We therefore re-tested selected samples from each CHMI cohort (2016, 2017 and 2018 – representative of samples with no parasites, low, and high parasitaemia) against a final set of standards, and normalized quantities against a WHO standard (35). After completion of the study, a subset of 1 mL whole blood samples were also shared with external laboratories at Mahidol University (MU), Thailand and the University of Washington (UW), USA for their analytically sensitive qPCR and reverse transcription PCR (RT-PCR) assays, respectively (16, 22). The limit of detection of these assays was 10 parasites/mL for the MU qPCR assay (22) and 1 parasite/mL for the UW qRT-PCR assay(15).

### **Anti-malarial Drug Detection**

Anti-malarial drug concentrations were measured in all enrolled volunteers retrospectively at two time points, day before challenge (C-1) and eight days after challenge (C+8). Plasma samples were sent to two independent laboratories to determine plasma concentrations being: Strathmore University, Kenya and Mahidol-Oxford Tropical Medicine Research Unit (MORU), Thailand. Artemether and dihydroartemisinin (DHA) concentrations were measured at MORU; sulfadoxine, pyrimethamine, and chloroquine at Strathmore; and lumefantrine and desbutyl-lumefantrine at both laboratories. Anti-malarial drug concentrations were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) using previously published procedures (36) and adapted from the previously reported high-performance liquid chromatography (HPLC) method (37).

## **MSP2 Genotyping**

MSP2 genotyping and anti-malarial drug detection was carried out. MSP2 genotyping was performed on blood samples collected on the day of treatment initiation for all volunteers regardless of parasite outcome during CHMI. This was done by a nested PCR with amplification specific for FC27 and IC/3D7 allelic types with fragment size analysis by capillary electrophoresis as previously described (38).

## **Statistics**

The sample size for the study was based on considering analysis of outcome of CHMI in a multivariable model considering parameters other than PCR outcome. Assuming an  $r^2$  value of 0.3, with a power of 80% to detect a single variable to account for 0.15 of the variability in parasite growth. Nonparametric correlation test, spearman rank correlation, was used for comparisons. All analyses were performed either using STATA version (15.1) StataCorp 2017, Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC. All tests were performed at 5% significance level where  $p < 0.05$  was considered significant.

## **Study approval**

The study was conducted at the KEMRI Wellcome Trust Research Programme in Kilifi, Kenya and received ethical approval from the KEMRI Scientific and Ethics Review Unit (KEMRI//SERU/CGMR-C/029/3190) and the University of Oxford Tropical Research Ethics Committee (OxTREC 2-16). The study was registered on ClinicalTrials.gov (NCT02739763), conducted based on good clinical practice (GCP), and under the principles of the Declaration of Helsinki.

## **Author Contributions**

MCK, PCB, KvM, FN, BO, FaO and PB contributed to the study design; Protocol development was performed by MCK, PN, and PB. Conduct of the clinical trial was performed by PN, MH, JM, ON, AA, FrO, and JaO. Experiments and data acquisition was conducted by MCK, DK, JMN, AIA, PCC, KPC, ZL, SHH, IJ, DoK, SiK, RK, SaK, CK, NK, MI, JoM, VM, KSM, MoM, SCM, JeM, MiM, JdM, IN, MN, DO, DwO, JO, MOO, AMS, JS, NS, BS, JoT, JaT, JW, TNW, and MW. EO, NK, KeM, DM, GN, and MO acquired and curated data. PFB, YA, EJ, TLR, BKLS, and SLH were involved in manufacture of PfSPZ Challenge. MCK, EO, and PB analysed the data. MCK and PB wrote the manuscript.

## **Acknowledgments**

This work was supported by a Wellcome Trust grant (107499). We would like to thank all the study volunteers who participated in the CHMI-SIKA study without whom this study would not be possible. We are also very grateful to the larger study teams in Kilifi and Ahero specifically all the fieldworkers and community health workers who recruited volunteers, the data entry clerks, clinical, pharmacy, and laboratory teams; and the collaborating manufacturing, quality systems, regulatory, pharmaceutical operations and clinical teams at Sanaria Inc. without whom this work would not have been possible. We would also like to thank the diagnostic teams at Mahidol University and the University of Washington for their assistance. All the members of the CHMI-SIKA study team read and reviewed the manuscript. This manuscript is published with permission and/or approval of the Director KEMRI. See Supplemental Acknowledgements for members of the CHMI-SIKA Study Team.

## References

1. Cohen S, Mc GI, Carrington S. Gamma-globulin and acquired immunity to human malaria *Nature* 1961;192:733–737.
2. Fowkes FJI, Richards JS, Simpson JA, Beeson JG. The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis. *PLoS Med.* 2010;7(1):e1000218.
3. Kinyanjui SM, Bejon P, Osier FH, Bull PC, Marsh K. What you see is not what you get: Implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity. *Malar. J.* 2009;5-2875-8-242
4. Roestenberg M, Hoogerwerf M-A, Ferreira DM, Mordmüller B, Yazdanbakhsh M. Experimental infection of human volunteers. *Lancet Infect. Dis.* 2018;18(10):e312–e322.
5. Roestenberg M et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. *Am J Trop Med Hyg* 2013;88(1):5–13.
6. Shekalaghe S et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. *Am J Trop Med Hyg* 2014;91(3):471–480.
7. Hodgson SH et al. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. *Front. Microbiol.* 2014;5:686.
8. Mordmuller B et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. *Malar J* 2015;14(1):117.
9. Gómez-Pérez GP et al. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates. *Malar. J.* 2015;14(1):306.

10. Achan J et al. Serologic markers of previous malaria exposure and functional antibodies inhibiting parasite growth are associated with parasite kinetics following a *Plasmodium falciparum* controlled human infection *Clin. Infect. Dis.* 2019; doi:10.1093/cid/ciz740
11. Lell B et al. Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon. *Am J Trop Med Hyg* 2017;
12. Jongo SA et al. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of *Plasmodium falciparum* Sporozoite Vaccine in Tanzanian Adults. *Am. J. Trop. Med. Hyg.* 2018;99(2):338–349.
13. Kapulu MC et al. Controlled human malaria infection in semi-immune Kenyan adults (Chmi-sika): A study protocol to investigate in vivo *Plasmodium falciparum* malaria parasite growth in the context of pre-existing immunity [version 2; peer review: 2 approved]. *Wellcome Open Res.* 2019;3. doi:10.12688/wellcomeopenres.14909.2
14. Bejon P et al. Thick blood film examination for *Plasmodium falciparum* malaria has reduced sensitivity and underestimates parasite density. *Malar. J.* 2006; doi:10.1186/1475-2875-5-104
15. Hodgson SH et al. Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies. *Malar. J.* 2015; doi:10.1186/s12936-015-0541-6
16. Seilie AM et al. Beyond blood smears: Qualification of *Plasmodium* 18S rRNA as a biomarker for controlled human malaria infections. *Am. J. Trop. Med. Hyg.* 2019;100(6):1466–1476.
17. Mwangi TW, Ross A, Snow RW, Marsh K. Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. *J Infect Dis* 2005;191(11):1932–1939.

18. Moser KA et al. Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential. *Genome Med.* 2020;12(1). doi:10.1186/s13073-019-0708-9
19. Gérardin P et al. Prognostic value of thrombocytopenia in African children with falciparum malaria. *Am. J. Trop. Med. Hyg.* (2002); doi:10.4269/ajtmh.2002.66.686
20. Watson J, Chu CS, Tarning J, Whitea NJ. Characterizing blood-stage antimalarial drug mic values in vivo using reinfection patterns. *Antimicrob. Agents Chemother.* 2018; doi:10.1128/AAC.02476-17
21. Chotsiri P et al. Severe Acute Malnutrition Results in Lower Lumefantrine Exposure in Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria. *Clin. Pharmacol. Ther.* 2019; doi:10.1002/cpt.1531
22. Imwong M et al. High-throughput ultrasensitive molecular techniques for quantifying low-density malaria parasitemias. *J. Clin. Microbiol.* 2014; doi:10.1128/JCM.01057-14
23. Collins KA et al. A controlled human malaria infection model enabling evaluation of transmission-blocking interventions. *J. Clin. Invest.* 2018;128(4):1551–1562.
24. McCarthy JS et al. A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study. *Malar. J.* 2016;15(1). doi:10.1186/s12936-016-1511-3
25. Reuling IJ et al. Liver Injury in Uncomplicated Malaria is an Overlooked Phenomenon: An Observational Study. *EBioMedicine* 2018;36:131–139.
26. Woodford J, Shanks GD, Griffin P, Chalon S, McCarthy JS. The dynamics of liver function test abnormalities after Malaria infection: A retrospective observational study. *Am. J. Trop. Med. Hyg.* 2018;98(4):1113–1119.
27. Dondorp AM, van der Pluijm RW, Day NP, White NJ. Letter to the editor RE: Reuling et al., 2018 liver injury in uncomplicated malaria is an overlooked phenomenon: An


- observational study 2019; *EBioMedicine* 2021;68. doi:10.1016/j.ebiom.2021.103377
28. Artemether-lumefantrine treatment of uncomplicated *Plasmodium falciparum* malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. *BMC Med.* 2015; doi:10.1186/s12916-015-0456-7
29. Smith N et al. Accessibility, availability and affordability of anti-malarials in a rural district in Kenya after implementation of a national subsidy scheme. *Malar. J.* 2011; doi:10.1186/1475-2875-10-316
30. Lohy Das JP et al. Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar. *Malar. J.* 2018; doi:10.1186/s12936-018-2278-5
31. Hermsen CC et al. Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. *Am. J. Trop. Med. Hyg.* 2004;71(2):196–201.
32. Takala SL et al. Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. *PLoS Med.* 2007; doi:10.1371/journal.pmed.0040093
33. Snow RW et al. The prevalence of *Plasmodium falciparum* in sub-Saharan Africa since 1900. *Nature* 2017;550(7677):515–518.
34. Ogwang C et al. Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with *Plasmodium falciparum* Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults. *PLoS One* 2013;8(3):e57726.
35. Cunningham JA et al. WHO malaria nucleic acid amplification test external quality assessment scheme: Results of distribution programmes one to three. *Malar. J.* 2020; doi:10.1186/s12936-020-03200-0
36. Hanpithakpong W et al. A liquid chromatographic-Tandem mass spectrometric method for determination of artemether and its metabolite dihydroartemisinin in human plasma.

*Bioanalysis* 2009; doi:10.4155/bio.09.6

37. Lindegårdh N et al. Development and validation of a bioanalytical method using automated solid-phase extraction and LC-UV for the simultaneous determination of lumefantrine and its desbutyl metabolite in plasma. In: *J Pharm and Biomedical Analysis*. 2005:


38. Khaemba EN et al. Comparing drug regimens for clearance of malaria parasites in asymptomatic adults using PCR in Kilifi County, Kenya: an open-label randomised controlled clinical trial (MalPaC). *Wellcome Open Res.* 2020; doi:10.12688/wellcomeopenres.15627.1

## Figures legends



**Figure 1 Study design and volunteer eligibility and enrolment for CHMI**

<sup>1</sup>One volunteer was both HIV and Hepatitis B positive; <sup>2</sup>Volunteers were assessed in the fourth quarter of 2017 but were not enrolled for CHMI due to national security reasons; \*Volunteers were deemed to have completed CHMI if they had received endpoint treatment. qPCR outcomes are presented for 142 after exclusions for parasite genotype and anti-malarial drug levels.



**Figure 2 qPCR outcome based on volunteer location**

Blood samples from C+8 (C+7.5 for Nairobi) onwards after inoculation to determine parasitaemia from: (A) Nairobi – N=27; (B) Kilifi North – N=34; (C) Kilifi South – N=93; and (D) Ahero – N=15. Parasitaemia was determined by asexual *18S* ribosomal RNA gene qPCR done in Kilifi. Blue lines represent individuals who required treatment and reached treatment threshold (reached DoT); green lines represent individuals who did not meet criteria for treatment threshold but were qPCR positive; orange lines represent individuals who were qPCR negative throughout monitoring; and red dot denotes individuals were febrile and met treatment criteria.

## Tables

**Table 1. Volunteer baseline characteristics based on location**

	<b>Ahero (N=15)</b>	<b>Kilifi North (N=34)</b>	<b>Kilifi South (N=112)</b>	<b>Total (N=161)</b>
Age, years	30.7 (7.1)	28.5 (7.6)	29.7 (6.7)	29.5 (7.1)
Female, % (n/N)	46.7% (7/15)	20.6% (7/34)	30.4% (34/112)	29.9% (48/161)
Male, % (n/N)	53.3 (8/15)	79.4 (27/34)	69.6 (78/112)	70.1 (113/161)
BMI, kg/m <sup>2</sup>	24.8 (6.9)	22.1 (3.5)	23.1 (3.7)	23.1 (4.1)
qPCR positive*	0.0% (0/15)	5.8% (2/34)	25.0% (28/112)	18.6% (30/161)

BMI, Body mass index. qPCR, quantitative polymerase chain reaction. Data are presented as either mean and (SD) or % and (n/N). \*qPCR positive at screening and were treated with Artemether for 7 days and qPCR confirmed to have cleared parasites either at C-9 or C-3.

**Table 2. Adverse events**

		<sup>1</sup> C+1-C+7	<sup>1</sup> C+8-DoT	<sup>2</sup> DoT-Exit	Total
Solicited Systemic	Headache	0	29 (18)	54 (33.5)	66 (41)
	Fever	0	18 (11.2)	28 (17.4)	39 (24.2)
	Fatigue	0	15 (9.3)	29 (18)	36 (22.4)
	Myalgia	0	8 (5)	15 (9.3)	18 (11.2)
	Arthralgia	0	7 (4.3)	16 (9.9)	20 (12.4)
	Chills	0	7 (4.3)	16 (9.9)	19 (11.8)
	Sweating	0	7 (4.3)	21 (13)	25 (15.5)
	Low back pain	0	6 (3.7)	10 (6.2)	14 (8.7)
	Abdominal pain	0	4 (2.5)	10 (6.2)	13 (8.1)
	Rigor	0	4 (2.5)	13 (8.1)	14 (8.7)
	Anorexia	0	3 (1.9)	9 (5.6)	11 (6.8)
	Diarrhoea	0	2 (1.2)	4 (2.5)	6 (3.7)
	Nausea	0	2 (1.2)	8 (5)	10 (6.2)
	Vomiting	0	1 (0.6)	1 (0.6)	2 (1.2)
	Solicited Local	Pain at the injection site	3 (1.9)	2 (1.2)	0
Swelling		1 (0.6)	0	0	1 (0.6)
Redness		2 (1.2)	0	0	2 (1.2)
Unsolicited <sup>3</sup>	Headache	7 (4.3)	21 (13)	41 (25.5)	60 (37.3)
	URTI	5 (3.1)	8 (5)	3 (1.9)	15 (9.3)
	Others <sup>4</sup>	2 (1.2)	15 (9.3)	9 (5.6)	26 (16.1)
	Abdominal pain	1 (0.6)	5 (3.1)	6 (3.7)	12 (7.5)
	Arthralgia	1 (0.6)	7 (4.3)	17 (10.6)	24 (14.9)
	Ear pain discomfort	1 (0.6)	5 (3.1)	2 (1.2)	7 (4.3)
	Pain injection site	1 (0.6)	2 (1.2)	0	3 (1.9)
	Tinea	1 (0.6)	6 (3.7)	1 (0.6)	8 (5)
	Chills	0	4 (2.5)	8 (5)	12 (7.5)
	Diarrhoea	0	1 (0.6)	1 (0.6)	2 (1.2)
	Fatigue	0	10 (6.2)	16 (9.9)	25 (15.5)
	Fever	0	14 (8.7)	19 (11.8)	32 (19.9)
	Low back pain	0	4 (2.5)	5 (3.1)	9 (5.6)
	Malaria	0	1 (0.6)	4 (2.5)	5 (3.1)
	Myalgia	0	3 (1.9)	14 (8.7)	17 (10.6)
	Nausea	0	2 (1.2)	3 (1.9)	5 (3.1)
	Rigors	0	2 (1.2)	9 (5.6)	11 (6.8)
	Sweating	0	4 (2.5)	12 (7.5)	15 (9.3)
	Swollen Limbs <sup>5</sup>	0	1 (0.6)	1 (0.6)	2 (1.2)
	Toothache	0	1 (0.6)	2 (1.2)	3 (1.9)
Vomiting	0	1 (0.6)	0	1 (0.6)	

<sup>1</sup>C+1-C+7 refers to day 1 to day 7 after challenge, C+8-DoT refers to day 8 after challenge to day of treatment; <sup>2</sup>DoT-Exit refers to period of observed treatment to in-patient exit; <sup>3</sup>There are instances of double reporting of the adverse events; <sup>4</sup>Other events include tinea, dental caries, oral candidiasis, neck pain, rash, swollen left eye, hematoma at venipuncture site etc.; <sup>5</sup>One participant had an ankle sprain possibly due to sports during inpatient stay. \*Percentages expressed over the total sample challenged (N=161); All events reported were grade 1; Median duration of AE's in days: 1; min duration of AE's in days: <1; max duration of AE's in days: 70days but when excluding Tinea (11days).

**Table 3: Measured anti-malarial drug concentration by CHMI outcome**

	<b>MIC (ng/ml)</b>	<b>Volunteers meeting treatment criteria with &gt;MIC</b>	<b>Volunteers meeting treatment criteria with &lt;MIC</b>	<b>Volunteers meeting treatment criteria with undetectable levels</b>	<b><i>p</i> value (&lt;MIC vs undetectable)</b>
Artesunate	N/A	0.0% (0/0)	0.0% (0/0)	36.1% (58/161)	
Chloroquine	67	0.0% (0/0)	50.0% (1/2)	35.9% (57/159)	0.7
Lumefantrine	200	0.0% (0/12)	33.4% (25/73)	43.5% (33/76)	0.25
Pyrimethamine	100	0.0% (0/1)	0.0% (0/1)	36.3% (58/160)	0.45
Sulfadoxine	100	66.7% (2/3)	33.4% (1/3)	35.5% (56/158)	0.26

MIC: minimum inhibitory concentration based on published literature; N/A not applicable. Data are presented as % and (n/N) or otherwise specified. MICs are not well defined for Pyrimethamine or Sulfadoxine, and an arbitrary value is chosen based on levels seen in the first 24 hrs after sulfadoxine pyrimethamine use in adult volunteers.

**Table 4: Malaria diagnosis outcome based on location**

	<b>Nairobi (N=28)</b>	<b>Ahero (N=15)</b>	<b>Kilifi North (N=34)</b>	<b>Kilifi South (N=93)</b>
PCR (-)	0.0% (0/28)	20.0% (3/15)	5.9% (2/34)	30.1% (28/93)
Treated, febrile	11.1% (3/28)	6.7% (1/15)	52.9% (18/34)	6.5% (6/93)
Treated, non-febrile	85.7% (24/28)	13.3% (2/15)	35.3% (12/34)	11.8% (11/93)
Untreated but PCR (+)	3.5% (1/28)	60.0% (9/15)	5.9% (2/34)	51.6% (48/93)

Data are presented as % and (n/N) or otherwise specified. PCR (-) refers to PCR negative; PCR (+) refers to PCR positive.